Abstracts tagged "Vasculitis"

Abstract Number: 2522 • ACR Convergence 2024
Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Kerem Abacar¹, Ayşe Elif Boncukcuoğlu¹, Aysun Aksoy², Derya Kocakaya¹, Çagatay Cimşit¹, Haner Direskeneli³ and Fatma Alibaz Öner³, ¹Marmara University, istanbul, Turkey, ²Alaaddin Keykubat University, Antalya, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
Abstract Number: 0724 • ACR Convergence 2024
Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Salma Al Fazazi³, Vanesa Calvo-Rio⁴, Mónica Renuncio-García⁵, Adrián Martín-Gutiérrez⁶, Amparo Sánchez-López⁷, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁷, Maria Rodríguez-Vidriales¹ and Ricardo Blanco-Alonso⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, ³Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
Abstract Number: 0757 • ACR Convergence 2024
Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis
Anna Kernder¹, Lena Noack¹, Adina Morar¹, Lara Burg², Torsten Lowin¹, Dennis Bleck¹, matthias schneider¹, Jörg Distler³, Georg Pongratz⁴ and Valentin S. Schäfer⁵, ¹Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Düsseldorf, Germany, ²Department of Rheumatology and Clinical Immunology, Clinic of Internal Medicine III, University Hospital of Bonn, Germany, Bonn, Germany, ³Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, ⁴Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Regensburg, Germany, ⁵University Hospital Bonn, Bonn, Germany
Background/Purpose: The immunopathogenesis of giant cell arteritis (GCA) remains unclear. It is known that monocytes are recruited from peripheral blood, infiltrate the vessel wall, and…
Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 1621 • ACR Convergence 2024
Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
Ufuoma Mamoh¹, Soziema Salia¹, Joan Morny², Jesse Odion³, Elem Ewuru⁴, Precious Onobraigho⁵, Eugene Omoike⁵, Oyidia Ijioma⁶, Osaruese Ezomo⁷ and Ehizogie Edigin⁸, ¹Medstar Union Memorial Hospital, Baltimore, MD, ²Piedmont Athens Regional Medical Center, Athens, GA, ³Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom, ⁴Acute and Emergency Care United Kingdom Medway Maritime Hospital, Gillingham, ⁵College of Medicine, University of Benin, Benin, Nigeria, ⁶Department of Clinical Psychiatry, University of South Wales, Wales, United Kingdom, ⁷Department of Gastroenterology, Spire Manchester Hospital, Manchester, United Kingdom, ⁸The University of Texas Health Science Center, houston, TX
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis, typically affecting young children, and is the leading cause of acquired heart disease in children in developed…
Abstract Number: 1962 • ACR Convergence 2024
Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis
Nouran Eshak¹, Kristina Yancey², Felipe Martinez³, Lester Mertz¹, carolyn mead harvey⁴, Kenneth Warrington⁵, Matthew Koster⁵ and Megan Sullivan¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ, ³Mayo Clinic Arizona, Phoenix, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Rochester, MN
Background/Purpose: Medium vessel vasculitis (MVV), including polyarteritis nodosa (PAN), presents significant diagnostic challenges with patients frequently exhibiting non-specific systemic manifestations. While 18F-fluorodeoxyglucose PET/CT (PET/CT) is…
Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir-Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci-Yildirim⁷, Zeliha Ademoglu⁸, Elif Ediboglu⁹, Burcu Ceren Uludogan¹⁰, Nazife Sule yaşar Bile¹⁰, Timucin Kasifoglu¹¹, Servet Akar¹², Hakan Emmungil⁸, Fatos Onen⁷, Ahmet Omma¹³, Nilüfer Alpay Kanıtez¹⁴, Ayten Yazici¹⁵, Ayse Cefle¹⁵, Murat Inanc³, Kenan Aksu¹⁶, Gokhan Keser¹⁷, Haner Direskeneli¹⁸ and Fatma Alibaz Öner¹⁸, ¹Bahcesehir University Faculty of Medicine, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁸Trakya University, Edirne, Turkey, ⁹Mayo Clinic, Rochester, MN, ¹⁰Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹¹Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ¹²Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹³Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁴Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁵Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹⁶Ege University Faculty of Medicine, Izmir, Turkey, ¹⁷Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ¹⁸Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
Abstract Number: 0760 • ACR Convergence 2024
A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis
Kevin Chevalier¹, Léa Dionet¹, Paul Breillat¹, Margot Poux¹, Julien Dang¹, Benoit Terris², Patrick Bruneval³, Luc Mouthon⁴, Olivia Lenoir¹, Tharaux Pierre-Louis¹ and Benjamin Terrier⁵, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ³Department of Pathology, Hôpital Européen Georges Pompidou, GHU Paris Centre, AP-HP, Université Paris Cité, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis affecting large vessels. The role of macrophages and vascular smooth muscle cells (VSMC) appears to be…
Abstract Number: 1106 • ACR Convergence 2024
Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Clara Moriano⁴, Javier Narvaez-García⁵, Vicente Aldasoro⁶, Olga Maíz Alonso⁷, Iñigo Hernández-Rodríguez⁸, Paloma Vela-Casasempere⁹, Susana Romero Yuste¹⁰, Eugenio De Miguel¹¹, Eva Galindez-Agirregoikoa¹², Jesus C. Fernandez-López¹³, ivan Ferraz-Amaro¹⁴, Julio Sánchez-Martín¹⁵, José Luis Callejas¹⁶, Patricia Moya Albarado¹⁷, Cristina Campos Fernández¹⁸, Fernando Lopez-Gutierrez¹⁹, Santos Castañeda²⁰ and Ricardo Blanco-Alonso²¹, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital León, LEON, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ⁸Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario La Paz, Madrid, Spain, ¹²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹³11Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, ¹⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁷Hospital de San Pau, Barcelona, Spain, ¹⁸Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²⁰Hospital Universitario de la Princesa, Madrid, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
Abstract Number: 1623 • ACR Convergence 2024
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez-Álvaro², Javier Narvaez-García³, Noemí Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez-Martín¹¹, Itziar Calvo¹², Vicente Aldasoro¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, Patricia Moya¹⁶, María García-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, San Sebastián, Spain, ¹⁰Hospital León, LEON, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Hospital Universitario de Basurto, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁷Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁸Hospital Universitario de la Princesa, Madrid, Spain, ¹⁹University of Cantabria. IDIVAL, Santander, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a predominantly female vasculitis. There are several studies that attempt to report the differences in the presentation of this…
Abstract Number: 1983 • ACR Convergence 2024
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Aaron Teel¹, Adrian Grebowicz², Mats Junek³, Stephanie Garner⁴, Tom Appleton⁵ and Faiza Khokhar⁶, ¹London Health Sciences Centre, Sarnia, ON, Canada, ²Western University, London, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada, ⁶McMaster University, St. Joseph's Hamilton, Mississauga, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy that have been associated with immune-related adverse events (irAEs). These include multiple rheumatic diseases…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 2526 • ACR Convergence 2024
Development of the Hospital Emergency Advocacy & Treatment Kit (HEAT Kit) for Patients with Vasculitis
Sarah Jones¹, Pamela Squires² and Donna McArthur³, ¹Eosinophilic & Rare Disease Cooperative, Tucson, AZ, ²Eosinophilic & Rare Disease Cooperative, Tucson, ³Adjunct professor of nursing, Vanderbilt School of Nursing; Adjunct clinical professor, University of Arizona College of Nursing & Dept. of Neurology, Tucson, AZ
Background/Purpose: All forms of vasculitis are rare with patients frequently experiencing poor or extended care in the hospital and ED settings. The ERDC founder experienced…

« Previous Page
1
…
3
4
5
6
7
…
35
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].